BrainStorm Q1 net loss $2.1M; cash below $0.2M; NurOwn Phase 3 preparations ongoing

BRAINSTORM CELL THERAPEUTICS INC.

2026-Q1 EPS reported -$0.19

Net loss $2.1M ($0.19 per share) vs $2.9M ($0.45) in Q1 2025; operating loss $2.0M.
Cash, equivalents, and restricted cash $0.2M at March 31, 2026, down from $0.3M at Dec 31, 2025.
R&D expense $0.8M (down from $1.3M); G&A expense $1.3M (down from $1.8M).
Planning Phase 3b ENDURANCE trial of NurOwn for ALS, targeting ~200 patients; BLA submission planned after Part A.
Raised $2M via two private placements in Feb 2026; stockholders' deficit $11M; accounts payable $7.3M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BRAINSTORM CELL THERAPEUTICS INC. reported the three months ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was approximately $2.1 million, EPS Net loss per share for the three months ended March 31, 2026 and 2025 was $(0.19) and $(0.45), respectively..

Period: the three months ended March 31, 2026
Net income: Net loss for the three months ended March 31, 2026 was approximately $2.1 million
EPS: Net loss per share for the three months ended March 31, 2026 and 2025 was $(0.19) and $(0.45), respectively.
Result: reported results

Exact text from the filing

BrainStorm Cell Therapeutics Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-062766

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.